Dearborn Partners LLC Makes New Investment in Pfizer Inc. $PFE

Key Points

• Dearborn Partners LLC initiated a Pfizer position in the second quarter, purchasing 40,635 shares valued at approximately $978,000. Institutional investors collectively own 68.36% of Pfizer’s stock.
• Pfizer and BioNTech received FDA approval for their updated 2026–2027 COVID-19 vaccine targeting the XFG variant, with shipments starting immediately and potential seasonal revenue benefits.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, exceeding analyst expectations, while Wall Street maintains an average “Hold” rating with a $28.28 price target. The company also declared a $0.43 quarterly dividend, representing a 6.1% annualized yield.

Dearborn Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 40,635 shares of the biopharmaceutical company's stock, valued at approximately $978,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $26,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its holdings in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Finally, Abound Financial LLC purchased a new position in shares of Pfizer during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. UBS Group reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and reduced their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Pfizer presently has an average rating of "Hold" and an average target price of $28.28.

Pfizer Stock Down 1.0%

Shares of NYSE PFE opened at $28.00 on Friday. The stock has a market cap of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The business has a 50-day moving average price of $25.49 and a 200 day moving average price of $26.29. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the company posted $0.78 EPS. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source